Carl Ola Landgren

List of Publications by Year
in descending order

288	16,578	34105 52	17592 121
papers	citations	h-index	g-index

300	300	300	13007
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chromothripsis as a pathogenic driver of multiple myeloma. Seminars in Cell and Developmental Biology, 2022, 123, 115-123.	5.0	22
2	Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica, 2022, 107, 284-286.	3.5	4
3	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncology, The, 2022, 23, 65-76.	10.7	80
4	Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions. Seminars in Oncology, 2022, , .	2.2	1
5	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. Nature Medicine, 2022, 28, 468-471.	30.7	19
6	Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Blood Cancer Journal, 2022, 12, 51.	6.2	2
7	Nutrition perceptions, needs and practices among patients with plasma cell disorders. Blood Cancer Journal, 2022, 12, 70.	6.2	7
8	Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood, 2022, 140, 491-503.	1.4	32
9	Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Leukemia and Lymphoma, 2022, 63, 2413-2421.	1.3	1
10	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2160-2166.	7.0	2
11	Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the <scp>CANDOR</scp> study. British Journal of Haematology, 2022, 198, 988-993.	2.5	5
12	Structural variants shape the genomic landscape and clinical outcome of multiple myeloma. Blood Cancer Journal, 2022, 12, .	6.2	7
13	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discovery, 2022, 3, 273-284.	5.0	24
14	Modern Myeloma Therapy + Sustained Minimal Residual Diseaseâ€“Negative = (Functional) Cure!. Journal of Clinical Oncology, 2022, 40, 2863-2866.	1.6	5
15	Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study. Leukemia and Lymphoma, 2022, 63, 2760-2761.	1.3	1
16	Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia, 2021, 35, 255-258.	7.2	48
17	Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. Blood Reviews, 2021, 46, 100732.	5.7	18
18	Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma. Clinical Cancer Research, 2021, 27, 15-23.	7.0	20

#	Article	IF	Citations
19	Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. JAMA Oncology, 2021, 7, 132.	7.1	21
20	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Clinical Cancer Research, 2021, 27, 2111-2118.	7.0	5
21	Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers. Environmental Health Perspectives, 2021, 129, 17003.	6.0	15
22	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications, 2021, 12, 293.	12.8	54
23	Positive selection as the unifying force for clonal evolution in multiple myeloma. Leukemia, 2021, 35, 1511-1515.	7.2	10
24	Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing. Journal of Molecular Diagnostics, 2021, 23, 181-199.	2.8	19
25	Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nature Communications, 2021, 12, 1861.	12.8	68
26	mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. Communications Biology, 2021, 4, 424.	4.4	21
27	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twiceâ€weekly carfilzomib (45 and 56â€‰mg/m²) in combination with lenalidomide and dexamethasone. American Journal of Hematology, 2021, 96, E193-E196.	4.1	10
28	Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. Pathology, 2021, 53, 385-399.	0.6	12
29	Familial patterns of hematologic precursors. Blood, 2021, 137, 1992-1993.	1.4	0
30	Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer Journal, 2021, 11, 94.	6.2	52
31	The mutagenic impact of melphalan in multiple myeloma. Leukemia, 2021, 35, 2145-2150.	7.2	32
32	Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. Clinica Chimica Acta, 2021, 516, 136-141.	1.1	7
33	Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. European Journal of Haematology, 2021, 107, 275-282.	2.2	8
34	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematology,the, 2021, 8, e422-e432.	4.6	50
35	Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. Leukemia, 2021, , .	7.2	8
36	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2021, 7, 862.	7.1	63

#	Article	IF	Citations
37	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212.	7.0	26
38	Pesticide use and kidney function among farmers in the Biomarkers of Exposure and Effect in Agriculture study. Environmental Research, 2021, 199, 111276.	7.5	17
39	Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. Nature Communications, 2021, 12, 5172.	12.8	27
40	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. JAMA Oncology, 2021, 7, 1678.	7.1	12
41	Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6479-6490.	7.0	9
42	A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. Blood, 2021, 138, 4759-4759.	1.4	1
43	Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms. Blood, 2021, 138, 3271-3271.	1.4	1
44	The Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations. Blood, 2021, 138, 2394-2394.	1.4	0
45	Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience. Blood, 2021, 138, 1644-1644.	1.4	7
46	Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities. Blood, 2021, 138, 4958-4958.	1.4	0
47	Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM). Blood, 2021, 138, 154-154.	1.4	0
48	Combination Venetoclax and Selinexor Effective in Relapsed/Refractory Multiple Myeloma with Translocation t(11;14). Blood, 2021, 138, 2270-2270.	1.4	1
49	Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study. Blood Cancer Journal, 2021, 11, 191.	6.2	7
50	Melphalan Flufenamide: a Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. Touch Reviews in Oncology & Haematology, 2021, 17, 101.	0.2	0
51	Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events. Hematology American Society of Hematology Education Program, 2021, 2021, 662-672.	2.5	11
52	Diagnosed with myeloma before age 40. Blood, 2021, 138, 2601-2602.	1.4	1
53	Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. Biology of Blood and Marrow Transplantation, 2020, 26, 204-208.	2.0	10
54	Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 58-65.	2.0	8

#	Article	IF	Citations
55	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e30-e37.	0.4	75
56	Future prospects of chimeric antigen receptor Tâ€cell therapy for multiple myeloma. Advances in Cell and Gene Therapy, 2020, 3, e72.	0.9	0
57	Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future. Best Practice and Research in Clinical Haematology, 2020, 33, 101140.	1.7	9
58	Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors. Thrombosis Research, 2020, 186, 86-92.	1.7	14
59	Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 198-200.	0.4	17
60	Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. Leukemia, 2020, 34, 1476-1480.	7.2	39
61	Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma. JAMA Oncology, 2020, 6, 425.	7.1	41
62	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2020, 396, 186-197.	13.7	299
63	Accelerated single cell seeding in relapsed multiple myeloma. Nature Communications, 2020, 11, 3617.	12.8	41
64	Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncology, The, 2020, 21, e540.	10.7	6
65	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood Cancer Discovery, 2020, 1, 234-243.	5.0	46
66	Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment. Blood Cancer Journal, 2020, 10, 76.	6.2	9
67	Management of multiple myeloma during COVID-19 pandemic. Leukemia Research Reports, 2020, 14, 100212.	0.4	2
68	A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor. JNCI Cancer Spectrum, 2020, 4, pkz104.	2.9	10
69	Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 2040-2046.	2.0	1
70	Revealing the Impact of Structural Variants in Multiple Myeloma. Blood Cancer Discovery, 2020, 1, 258-273.	5.0	81
71	Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma. American Journal of Surgical Pathology, 2020, 44, 838-848.	3.7	22
72	Mass Spectrometryâ€"Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma. Journal of Molecular Diagnostics, 2020, 22, 901-911.	2.8	22

#	Article	IF	Citations
73	The role of highâ€dose melphalan with autologous stemâ€cell transplant in multiple myeloma: is it time for a paradigm shift?. British Journal of Haematology, 2020, 191, 692-703.	2.5	23
74	Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Investigational New Drugs, 2020, 38, 1448-1453.	2.6	58
75	B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer Journal, 2020, 10, 73.	6.2	36
76	Comparison of MALDIâ€TOF mass spectrometry analysis of peripheral blood and bone marrowâ€based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. British Journal of Haematology, 2020, 189, 904-907.	2.5	40
77	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia, 2020, 34, 1840-1852.	7.2	55
78	Multiple myeloma: Current advances and future directions. Best Practice and Research in Clinical Haematology, 2020, 33, 101155.	1.7	1
79	Fractures and survival in multiple myeloma: results from a population-based study. Haematologica, 2020, 105, 1067-1073.	3.5	29
80	Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. Best Practice and Research in Clinical Haematology, 2020, 33, 101148.	1.7	9
81	Second malignancies in multiple myeloma; emerging patterns and future directions. Best Practice and Research in Clinical Haematology, 2020, 33, 101144.	1.7	27
82	Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. Value in Health, 2020, 23, 441-450.	0.3	9
83	Timing the initiation of multiple myeloma. Nature Communications, 2020, 11, 1917.	12.8	99
84	CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. Radiology, 2020, 295, 606-615.	7.3	73
85	Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2020, 83, 269-278.	2.3	4
86	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 1394-1401.	2.0	8
87	Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. Blood, 2020, 136, 43-45.	1.4	10
88	Whole-Genome Sequencing Reveals Evidence of Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Myeloma Precursor Disease. Blood, 2020, 136, 47-48.	1.4	2
89	Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study. Blood, 2020, 136, 26-27.	1.4	13
90	Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study. Blood, 2020, 136, 32-34.	1.4	3

#	Article	IF	Citations
91	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 18-19.	1.4	0
92	Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls. Blood, 2020, 136, 44-45.	1.4	0
93	A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study). Blood, 2020, 136, 8-10.	1.4	0
94	VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. Blood, 2020, 136, 37-38.	1.4	1
95	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 7-7.	1.4	1
96	Influence of Aging Processes on the Biology and Outcome of Multiple Myeloma. Blood, 2020, 136, 8-9.	1.4	2
97	The Genomic Complexity of Multiple Myeloma Precursor Disease Can be Predicted Using Copy Number Signatures on Targeted Sequencing and SNP Array Data. Blood, 2020, 136, 10-10.	1.4	1
98	The Role of 18f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd). Blood, 2020, 136, 11-12.	1.4	0
99	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Blood, 2020, 136, 50-51.	1.4	0
100	Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients. Blood, 2020, 136, 52-53.	1.4	2
101	Duration of Post-Autologous Hematopoietic Cell Transplant Anemia and Thrombocytopenia Are Associated with Prolonged Hospital Length-of-Stay for Multiple Myeloma Patients. Blood, 2020, 136, 5-6.	1.4	0
102	Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients. Blood, 2020, 136, 26-28.	1.4	2
103	Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma. Blood, 2020, 136, 28-28.	1.4	8
104	Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood Cancer Journal, 2019, 9, 59.	6.2	9
105	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. JAMA Oncology, 2019, 5, 1293.	7.1	57
106	Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia, 2019, 33, 2127-2143.	7.2	36
107	Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Scientific Reports, 2019, 9, 14884.	3.3	3
108	Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. American Journal of Hematology, 2019, 94, 1364-1373.	4.1	22

#	Article	IF	Citations
109	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. Cancer Immunology Research, 2019, 7, 1047-1053.	3.4	59
110	Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. PLoS ONE, 2019, 14, e0211600.	2.5	24
111	Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. American Journal of Hematology, 2019, 94, 794-802.	4.1	10
112	Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a populationâ€based study. British Journal of Haematology, 2019, 186, 37-44.	2.5	0
113	Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood Cancer Journal, 2019, 9, 15.	6.2	30
114	Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay. journal of applied laboratory medicine, The, 2019, 3, 857-863.	1.3	23
115	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology, 2019, 291, 5-13.	7.3	209
116	Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e213-e220.	0.4	9
117	Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Advances, 2019, 3, 2040-2044.	5.2	50
118	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer Journal, 2019, 9, 101.	6.2	40
119	Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database. Biology of Blood and Marrow Transplantation, 2019, 25, 41-46.	2.0	15
120	Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms. Journal of Molecular Diagnostics, 2019, 21, 330-342.	2.8	69
121	Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2019, 25, e89-e97.	2.0	12
122	Meeting report: Advances in minimal residual disease testing in multiple myeloma 2018. Advances in Cell and Gene Therapy, 2019, 2, e26.	0.9	19
123	A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). Blood, 2019, 134, 3116-3116.	1.4	23
124	VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis. Blood, 2019, 134, 1835-1835.	1.4	7
125	A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or NaÃ¯ve to Daratumumab (dara). Blood, 2019, 134, 1867-1867.	1.4	5
126	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2019, 134, 3127-3127.	1.4	2

#	Article	IF	Citations
127	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. Blood, 2019, 134, 862-862.	1.4	34
128	Revealing the Impact of Recurrent and Rare Structural Variations in Multiple Myeloma. Blood, 2019, 134, 576-576.	1.4	5
129	Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies. Blood, 2019, 134, 1891-1891.	1.4	9
130	MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy. Blood, 2019, 134, 4377-4377.	1.4	2
131	Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma.. Journal of Clinical Oncology, 2019, 37, e19525-e19525.	1.6	1
132	Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases. Blood, 2019, 134, 5444-5444.	1.4	1
133	Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma. Blood, 2019, 134, 3060-3060.	1.4	0
134	FDA Analysis: Impact of Body Mass Index (BMI) on Outcomes in Relapsed-Refractory Multiple Myeloma. Blood, 2019, 134, 5505-5505.	1.4	0
135	Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree. Blood, 2019, 134, 1794-1794.	1.4	0
136	High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster. Blood, 2019, 134, 3720-3720.	1.4	1
137	Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma. Blood, 2019, 134, 4367-4367.	1.4	0
138	Timing the Initiation of Multiple Myeloma. Blood, 2019, 134, 573-573.	1.4	0
139	Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a "Spike-in" Clonal Sequence. Blood, 2019, 134, 3380-3380.	1.4	0
140	An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma. Blood, 2019, 134, 5554-5554.	1.4	0
141	Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. European Journal of Haematology, 2018, 101, 237-244.	2.2	107
142	Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. Biology of Blood and Marrow Transplantation, 2018, 24, 871-876.	2.0	35
143	Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia and Lymphoma, 2018, 59, 1981-1985.	1.3	16
144	Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. Bone Marrow Transplantation, 2018, 53, 1445-1449.	2.4	12

#	Article	IF	Citations
145	Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster. JAMA Oncology, 2018, 4, 821.	7.1	38
146	MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. Seminars in Hematology, 2018, 55, 44-50.	3.4	31
147	Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica, 2018, 103, e412-e415.	3.5	87
148	MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool. Seminars in Hematology, 2018, 55, 1-3.	3.4	25
149	Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clinical Biochemistry, 2018, 51, 66-71.	1.9	49
150	Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Leukemia and Lymphoma, 2018, 59, 178-186.	1.3	2
151	Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma. Leukemia and Lymphoma, 2018, 59, 221-224.	1.3	12
152	CAR T cell therapy for multiple myeloma: where are we now and where are we headed?. Leukemia and Lymphoma, 2018, 59, 2056-2067.	1.3	50
153	Host-related immunodeficiency in the development of multiple myeloma. Leukemia and Lymphoma, 2018, 59, 1127-1132.	1.3	16
154	Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone. JAMA Oncology, 2018, 4, 1781.	7.1	33
155	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nature Medicine, 2018, 24, 1867-1876.	30.7	179
156	Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS ONE, 2018, 13, e0206047.	2.5	19
157	Biological determinants of health disparities in multiple myeloma. Blood Cancer Journal, 2018, 8, 85.	6.2	29
158	Identifying Ultra-High Risk Smoldering Multiple Myeloma. Blood, 2018, 132, 3192-3192.	1.4	1
159	A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up. Blood, 2018, 132, 1957-1957.	1.4	2
160	Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study. Blood, 2018, 132, 799-799.	1.4	7
161	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). Blood, 2018, 132, 1994-1994.	1.4	10
162	Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study. Blood, 2018, 132, 3281-3281.	1.4	4

#	Article	IF	Citations
163	Depth of Response and Outcomes in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Blood, 2018, 132, 4619-4619.	1.4	4
164	Continuous Mobile Wearable Bio-Monitoring of Newly Diagnosed Multiple Myeloma Patients Undergoing Initial Chemotherapy. Blood, 2018, 132, 4751-4751.	1.4	1
165	MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone. Blood, 2018, 132, 1983-1983.	1.4	2
166	Capture Rate of the Adaptive Next Generation Sequencing VDJ Assay in Multiple Myeloma. Blood, 2018, 132, 3184-3184.	1.4	3
167	Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial. Blood, 2018, 132, 959-959.	1.4	71
168	Peripheral Neuropathy Is Associated with an Increased Risk of Fractures in Individuals with Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study Including 15,351 MGUS Cases. Blood, 2018, 132, 1914-1914.	1.4	0
169	Measurement of Serum microRNAs in US Veterans with Monoclonal Gammopathy of Undetermined Significance. Blood, 2018, 132, 5576-5576.	1.4	0
170	Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience. Blood, 2018, 132, 5591-5591.	1.4	0
171	Whole Genome Sequencing of Extramedullary Myeloma Autopsy Tumors Reveals a Genomic Portrait at Culmination of Clonal Convergence. Blood, 2018, 132, 3169-3169.	1.4	1
172	Intestinal Microbiota Composition Is Associated with Minimal Residual Disease Negativity in Patients with Multiple Myeloma. Blood, 2018, 132, 3167-3167.	1.4	1
173	Risk Factors for Acute Myeloid Leukemia and Myelodysplastic Syndromes in Patients with Multiple Myeloma: An Updated Analysis. Blood, 2018, 132, 4437-4437.	1.4	0
174	Next-Generation Sequencing-Based Assay Shows High Clonal Characterization Success Rate for Plasma Cell Neoplasms, and Concordance with Flow Cytometry in Minimal Residual Disease Detection. Blood, 2018, 132, 4475-4475.	1.4	0
175	Mytype: A Capture Based Sequencing Approach to Detect Somatic Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma. Blood, 2018, 132, 5588-5588.	1.4	0
176	The Impact of Fractures on Survival in Multiple Myeloma: Results from a Population-Based Study. Blood, 2018, 132, 4490-4490.	1.4	0
177	Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leukemia and Lymphoma, 2017, 58, 1823-1831.	1.3	57
178	History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. Annals of Hematology, 2017, 96, 261-269.	1.8	20
179	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clinical Cancer Research, 2017, 23, 3980-3993.	7.0	71
180	Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leukemia and Lymphoma, 2017, 58, 2962-2965.	1.3	4

#	Article	IF	Citations
181	Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer Chemotherapy and Pharmacology, 2017, 80, 217-221.	2.3	3
182	Proteomic profiling in plasma cell disorders: a feasibility study. Leukemia and Lymphoma, 2017, 58, 1757-1759.	1.3	7
183	Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease. Obesity, 2017, 25, 1317-1320.	3.0	17
184	Racial/ethnic disparities: need more work!. Blood, 2017, 130, 1685-1686.	1.4	2
185	Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*. Leukemia and Lymphoma, 2017, 58, 1123-1129.	1.3	11
186	Serum protein markers of clonal heterogeneity in myeloma. Lancet Haematology,the, 2017, 4, e565-e566.	4.6	0
187	Shall we treat smoldering multiple myeloma in the near future?. Hematology American Society of Hematology Education Program, 2017, 2017, 194-204.	2.5	25
188	MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Advances, 2017, 1, 728-732.	5.2	84
189	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Advances, 2017, 1, 1911-1918.	5.2	37
190	Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study. Blood Advances, 2017, 1, 2790-2798.	5.2	23
191	Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Advances, 2017, 1, 2186-2192.	5.2	47
192	Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM. Blood, 2017, 130, 742-742.	1.4	92
193	Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status. Seminars in Oncology, 2016, 43, 703-706.	2.2	1
194	Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study. Annals of Hematology, 2016, 95, 871-879.	1.8	13
195	Myeloma imaging: time to move on!. Leukemia and Lymphoma, 2016, 57, 1499-1500.	1.3	3
196	Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood, 2016, 127, 2355-2356.	1.4	13
197	Monoclonal gammopathy of undetermined significance and WaldenstrÃ¶m's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 187-193.	1.7	5
198	MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer Treatment and Research, 2016, 169, 3-12.	0.5	39

#	Article	IF	Citations
199	Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry Part B - Clinical Cytometry, 2016, 90, 14-20.	1.5	35
200	Myeloma minimal residual disease testing in the United States: Evidence of improved standardization. American Journal of Hematology, 2016, 91, E502-E503.	4.1	18
201	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
202	A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. Seminars in Oncology, 2016, 43, 682-689.	2.2	53
203	New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma. Clinical Cancer Research, 2016, 22, 5428-5433.	7.0	98
204	Imaging Measurable (Minimal) Residual Disease in Multiple Myeloma. Current Radiology Reports, 2016, 4, 1.	1.4	0
205	Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. Leukemia and Lymphoma, 2016, 57, 1114-1121.	1.3	23
206	CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2016, 22, 258-267.	2.0	21
207	Whole Exome Sequencing from Nine Independent Sites of Extraosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution. Blood, 2016, 128, 2090-2090.	1.4	0
208	Survival in patients with familial and sporadic myeloproliferative neoplasms. Blood, 2015, 125, 3665-3666.	1.4	8
209	Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. Haematologica, 2015, 100, 1340-1349.	3.5	43
210	Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. Pharmacotherapy, 2015, 35, 1173-1188.	2.6	51
211	Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e493-e503.	3.8	11
212	The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma. JAMA Oncology, 2015, 1, 168.	7.1	93
213	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2015, 1, 746.	7.1	266
214	Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica, 2015, 100, 107-113.	3.5	356
215	Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nature Reviews Clinical Oncology, 2015, 12, 286-295.	27.6	97
216	Trends and Racial/Ethnic Disparities in Gluten-Sensitive Problems in the United States: Findings from the National Health and Nutrition Examination Surveys From 1988 to 2012. American Journal of Gastroenterology, 2015, 110, 455-461.	0.4	99

#	Article	IF	Citations
217	Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leukemia and Lymphoma, 2015, 56, 1416-1424.	1.3	23
218	Smoldering multiple myeloma. Blood, 2015, 125, 3069-3075.	1.4	211
219	Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. Journal of Molecular Diagnostics, 2015, 17, 669-678.	2.8	36
220	Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance. JAMA Oncology, 2015, 1, 1061.	7.1	56
221	Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 1785-1785.	1.4	4
222	The Majority of Patients with Relapsing Light Chain (AL) Amyloidosis Are Not Eligible for Enrollment Onto Clinical Trials: Using Screen Failures to Define Major Unmet Medical Needs. Blood, 2015, 126, 1786-1786.	1.4	1
223	Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study. Blood, 2015, 126, 3178-3178.	1.4	1
224	Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy. Blood, 2015, 126, 4257-4257.	1.4	8
225	Incidence and Management of Proteasome Inhibitor-Related Cardiotoxicity in Multiple Myeloma Patients at Memorial Sloan Kettering Cancer Center. Blood, 2015, 126, 4265-4265.	1.4	6
226	Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials. Blood, 2015, 126, 1975-1975.	1.4	0
227	Success of Online Curriculum-Based Education in the Management of Multiple Myeloma and Continuing Gaps Among Hematologists/Oncologists. Blood, 2015, 126, 3320-3320.	1.4	1
228	Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents. Blood, 2015, 126, 1996-1996.	1.4	5
229	How I treat smoldering multiple myeloma. Blood, 2014, 124, 3380-3388.	1.4	41
230	The Road to Treating Smoldering Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S59-S64.	0.4	2
231	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 87-97.	2.1	32
232	Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leukemia Research, 2014, 38, 371-376.	0.8	76
233	Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice. Clinical Cancer Research, 2014, 20, 804-813.	7.0	29
234	Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood, 2014, 123, 338-345.	1.4	105

#	Article	IF	Citations
235	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	10.7	3,343
236	A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica, 2014, 99, e81-e83.	3.5	112
237	Upfront Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients: An Update on Cost Analysis Study at Memorial Sloan Kettering Cancer Center. Blood, 2014, 124, 848-848.	1.4	1
238	Efficacy and Risk Factors Analysis of Upfront Autologous Stem Cell Mobilization Using Plerixafor and Granulocyte-Colony Stimulating Factor (GCSF) in Patients with Multiple Myeloma. Blood, 2014, 124, 3856-3856.	1.4	0
239	Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging â€œearly myelomaâ€• Leukemia and Lymphoma, 2013, 54, 1355-1363.	1.3	90
240	Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leukemia and Lymphoma, 2013, 54, 2215-2218.	1.3	86
241	Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica, 2012, 97, 854-858.	3.5	110
242	Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression. Leukemia and Lymphoma, 2012, 53, 721-724.	1.3	9
243	Early Myelodysplastic Changes Present in Substantial Proportion of Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Patients. Blood, 2012, 120, 1805-1805.	1.4	4
244	Appearance of Monoclonal Plasma Cell Diseases in Whole Body MRI in 544 Patients and Correlation with Parameters of Disease Activity. Blood, 2012, 120, 4966-4966.	1.4	1
245	Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma. Blood, 2012, 120, 570-570.	1.4	0
246	Role of MicroRNAs From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. Seminars in Hematology, 2011, 48, 39-45.	3.4	16
247	Multiple Myeloma Precursor Disease: Current Clinical Dilemma and Future Opportunities. Seminars in Hematology, 2011, 48, 1-3.	3.4	8
248	Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future. Seminars in Hematology, 2011, 48, 66-72.	3.4	7
249	Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood, 2011, 118, 4086-4092.	1.4	173
250	Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunities. Oncology, 2011, 25, 589-90.	0.5	9
251	Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood, 2010, 116, 1056-1059.	1.4	137
252	Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood, 2010, 116, 5501-5506.	1.4	308

#	Article	IF	Citations
253	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood, 2010, 115, 4991-4998.	1.4	204
254	Multiple Myeloma Precursor Disease. JAMA - Journal of the American Medical Association, 2010, 304, 2397.	7.4	48
255	Circulating Serum Free Light Chains As Predictive Markers of AIDS-Related Lymphoma. Journal of Clinical Oncology, 2010, 28, 773-779.	1.6	101
256	Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: New Insights into Pathophysiology and Epidemiology. Hematology American Society of Hematology Education Program, 2010, 2010, 295-302.	2.5	25
257	Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. Leukemia and Lymphoma, 2010, 51, 2159-2170.	1.3	25
258	Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas. European Journal of Clinical & Medical Oncology, 2010, 2, 119-126.	0.0	12
259	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood, 2009, 113, 5412-5417.	1.4	904
260	B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2009, 360, 659-667.	27.0	322
261	Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood, 2009, 113, 6386-6391.	1.4	137
262	Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood, 2009, 113, 4992-5001.	1.4	362
263	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood, 2009, 114, 791-795.	1.4	133
264	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica, 2009, 94, 1714-1720.	3.5	95
265	Isotype-Specific Heavy/Light Chain (HLC) Suppression as a Predictor of Myeloma Development in Monoclonal Gammopathy of Undetermined Significance (MGUS).. Blood, 2009, 114, 1788-1788.	1.4	6
266	African-American Multiple Myeloma Patients Have a Better Survival Than Caucasian Patients: a Population-Based Study Including 28,636 Patients.. Blood, 2009, 114, 1832-1832.	1.4	4
267	Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.. Blood, 2009, 114, 1872-1872.	1.4	2
268	Temporal Trends in the Proportion Cured Among Patients Diagnosed with Acute Myeloid Leukemia in Sweden 1973-2001, a Population-Based Study.. Blood, 2009, 114, 1378-1378.	1.4	0
269	Patterns of Monoclonal Immunoglobulins and Serum Free Light Chains Are Significantly Different in African-American Compared to Caucasian MGUS Patients.. Blood, 2009, 114, 2838-2838.	1.4	0
270	Improved Patient Survival and Cure for Hodgkin Lymphoma: A Population-Based Study of 6,136 Patients Diagnosed in Sweden 1973-2005.. Blood, 2009, 114, 1553-1553.	1.4	3

#	Article	IF	Citations
271	Obesity is Associated with a 2-Fold Elevated Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) Among African-American and Caucasian Women.. Blood, 2009, 114, 4876-4876.	1.4	0
272	Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24â€‰577 first-degree relatives of 11â€‰039 patients with myeloproliferative neoplasms in Sweden. Blood, 2008, 112, 2199-2204.	1.4	226
273	Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003. Journal of Clinical Oncology, 2007, 25, 1993-1999.	1.6	275
274	Risk of Malignant Disease Among 1525 Adult Male US Veterans With Gaucher Disease. Archives of Internal Medicine, 2007, 167, 1189.	3.8	38
275	Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood, 2007, 109, 2198-2201.	1.4	89
276	Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana. Mayo Clinic Proceedings, 2007, 82, 1468-1473.	3.0	142
277	New Aspects in Descriptive, Etiologic, and Molecular Epidemiology of Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America, 2007, 21, 825-840.	2.2	40
278	Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. British Journal of Haematology, 2007, 139, 791-798.	2.5	52
279	Autoimmunity and Susceptibility to Hodgkin Lymphoma: A Population-Based Caseâ€“Control Study in Scandinavia. Journal of the National Cancer Institute, 2006, 98, 1321-1330.	6.3	179
280	Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood, 2006, 107, 904-906.	1.4	280
281	Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood, 2006, 108, 292-296.	1.4	63
282	Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. International Journal of Cancer, 2006, 118, 3095-3098.	5.1	125
283	Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. International Journal of Cancer, 2006, 120, 1099-1102.	5.1	39
284	Risk of Multiple Myeloma following Medication Use and Medical Conditions: A Case-Control Study in Connecticut Women. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2342-2347.	2.5	55
285	Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia. Haematologica, 2006, 91, 1697-700.	3.5	35
286	Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Subsequent Multiple Myeloma among African-American and White Veterans in the U.S.. Blood, 2005, 106, 1541-1541.	1.4	1
287	Timing the Initiation of Multiple Myeloma. SSRN Electronic Journal, 0, , .	0.4	4
288	Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. Leukemia and Lymphoma, 0, , 1-10.	1.3	1